The SCICONX Journal of Advances in Diabetes Biology (JADB) is committed to maintaining the highest standards of scientific integrity, transparency, and editorial independence. This Editorial Policy outlines the principles and procedures governing manuscript evaluation, publication ethics, authorship standards, data integrity, and editorial decision-making.
Our mission is to ensure that all published content reflects rigorous scientific methodology, ethical research conduct, and meaningful contribution to the field of diabetes biology.
1. Editorial Independence
JADB operates under full editorial independence. Editorial decisions are based solely on:
Editorial decisions are not influenced by commercial interests, institutional affiliations, funding sources, or personal relationships.
2. Scope and Content Standards
Manuscripts submitted to JADB must align with the journal’s focus on biological mechanisms underlying diabetes and metabolic dysfunction. Priority is given to research that:
Submissions that fall outside the defined scope may be declined at the initial editorial screening stage.
3. Peer Review Integrity
JADB follows a structured double-blind peer review process to ensure unbiased evaluation.
Review Principles
Editors oversee reviewer selection to minimize conflicts of interest and maintain subject-matter relevance.
4. Authorship Criteria
Authorship must reflect substantial scholarly contribution. All listed authors must have:
Guest, honorary, or ghost authorship is strictly prohibited.
5. Conflict of Interest Disclosure
All authors, editors, and reviewers must disclose potential conflicts of interest, including:
Conflict disclosures are evaluated during editorial review and may be published alongside accepted articles when relevant.
6. Research Ethics Compliance
Human Subjects Research
Studies involving human participants must:
Animal Research
Animal studies must:
Failure to provide adequate ethical documentation may result in rejection.
7. Data Transparency and Reproducibility
JADB promotes research reproducibility and transparency. Authors are encouraged to:
Editors may request additional data or clarification during review if necessary.
8. Plagiarism and Research Misconduct
JADB enforces strict policies against:
All submissions undergo similarity screening. Suspected misconduct is investigated according to established publishing ethics procedures. Confirmed violations may result in:
9. Corrections, Retractions, and Updates
If significant errors are identified after publication, JADB will take appropriate corrective action, including:
Retractions are conducted transparently and clearly labelled to preserve the integrity of the scholarly record.
10. Appeals and Complaints
Authors may submit formal appeals against editorial decisions. Appeals must:
Appeals are reviewed independently by senior editorial leadership. Decisions after appeal are final.
11. Editorial Confidentiality
Editors and reviewers must maintain strict confidentiality regarding:
Unpublished data may not be used for personal research or shared externally.
12. Artificial Intelligence and Emerging Technologies
Authors using AI-based tools for data analysis, language editing, or modeling must:
AI tools cannot be listed as authors.
13. Advertising and Commercial Influence
JADB maintains a strict separation between editorial decisions and any commercial or advertising activities. Sponsorship or financial contributions do not influence publication outcomes.
14. Open Access Policy
JADB is an open-access journal. All accepted articles:
Authors retain copyright while granting publishing rights to the journal.
15. Continuous Policy Review
Editorial policies are periodically reviewed and updated to align with evolving best practices in scholarly publishing. Revisions are communicated transparently on the journal website.
Commitment to Excellence
The SCICONX Journal of Advances in Diabetes Biology (JADB) is dedicated to fostering a culture of ethical scholarship, scientific rigor, and responsible publication. Through clear editorial governance and transparent processes, we aim to build a trusted platform that advances global research in diabetes biology.